8 / 12
1 5
t h
I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology
Journal of Clinical Immunology and Allergy
ISSN 2471-304X
J u l y 0 5 - 0 7 , 2 0 1 8
V i e n n a , A u s t r i a
Immunology 2018
Page 47
M
icroRNAs (miRNAs) constitute a biologically very important class of small,
noncoding RNAs, about 18–22 nucleotides (nt) long, that mainly act as
negative regulators of gene expression at posttranscriptional level by controlling
the translation and stability of mRNA target. It is known that a miRNA may target
several mRNAs as well as the mRNA that can be under the control of several
miRNAs. The dysregulation of miRNAs has been frequently observed in different
types of disease, including cancer, autoimmune driven diseases, many allergies,
metabolic pathologies. All these data make it possible to identify microRNAs
as almost ideal targets for human therapeutics. In spite of numerous attempts
in this direction, many therapeutic trials have finally failed due to methodological
difficulties sometimes, but mainly because of insurmountable adverse effects.
In recent years, we have developed a nanotherapy using ultra-low doses of
microRNAs (concentrations are of the order of the nanogram) administered
sub-lingually, which we called Bio Immune(G)ene Medicine, and which allows to
use microRNAs for therapeutic purposes without particular difficulty. A number
of clinical examples should illustrate the methodology used and highlight the
therapeutic efficacy of this highly innovative new medical approach of multiple
chronic diseases.
Biography
Gilbert Glady Born in Strasbourg, France, Dr. Gilbert Glady grad-
uated from Medical School in 1977 and was then an intern in
onco-hematology at the university clinic for several years. After
a specialization in homeopathy and naturopathy in Paris, he
returned to the Alsace region to work as a private practitioner.
Through his work and encounters, he developed interest and
expertise in immunology and immunogenetics, that leaded him
to nanomedicine and nanobiotechnology. He thus became in
2010 the creator of the BI(G)MED method (Bio Immune (G)ene
Medicine) and director of EBMA, the European association re-
sponsible for communication and trainings in the field of BI(G)
MED. He has participated in numerous international congress-
es in immuno-allergology, infectiology and oncology with post-
ers and oral presentations, and is the author of several publica-
tions on nanobiotherapy in different journals.
info@ebma-europe.comTherapeutic use of microRNAs in different
types of immune diseases
Gilbert Glady
European Bio Immune(G)ene Medicine Association, France
Gilbert Glady, Insights Allergy Asthma Bronchitis 2018, Volume: 4
DOI: 10.21767/2471-304X-C1-001